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Figure S-1. Structure of compound 5a in the solid state. Anisotropic displacement 
parameters are drawn at the 50% probability level, hydrogen atoms are omitted for clarity. 
 
 
X-ray Crystal Structure Analysis of Compound 5a. C8 H12 O2, Mr = 140.18  g · mol
-1, colorless 
plate, crystal size 0.33 x 0.09 x 0.04 mm, monoclinic, space group P21/c, a =  7.3045(4) Å, b = 
7.2696(4) Å, c = 15.0537(9) Å, β = 94.071(3)°, V = 797.35(8) Å3, T = 100 K, Z = 4, Dcalc = 1.168  
g·cm3,  = 1.54178 Å, (Cu-K) = 0.670 mm-1, Empirical absorption correction (Tmin = 0.84, 
Tmax = 0.98), Bruker AXS Proteum X8 diffractometer,  5.89 <  < 65.08°, 17835 measured 
reflections, 1359 independent reflections, 1069 reflections with I > 2(I), Structure solved by 
direct methods and refined by full-matrix least-squares against F2 to R1 = 0.052 [I > 2(I)], 
wR2 =  0.132, 96 parameters, extinction coefficient = 0.010(2), H atoms riding,  S =  1.039, 
residual electron density 0.3 / -0.2 e Å-3. 
 
CCDC-953753 contains the supplementary crystallographic data for this paper. This information can 






Determination of the Stereostructure by NMR 
 
According to a previous study,1 the four possible isomers of 3,5-dimethyl-2,4-alkadienoic acids show 
the following characteristic signals in their 1H NMR and 13C NMR spectra (CDCl3): 
 
(2Z, 4E): Meb : ≈ 2.03 ppm; Hb: ≈ 6.46 ppm 
(2Z, 4Z): Meb : ≈ 2.03 ppm; Hb: ≈ 6.40 ppm 
(2E, 4E): Meb : ≈ 2.25 ppm; Hb: ≈ 5.72 ppm 
(2E, 4Z): Meb : ≈ 2.25 ppm; Hb: ≈ 5.73 ppm 
 
(2Z, 4E): Meb : ≈ 18.5 ppm; Mea : ≈ 25.5 ppm 
(2Z, 4Z): Meb : ≈ 25.5 ppm; Mea : ≈ 23.7 ppm 
(2E, 4E): Meb : ≈ 19.6 ppm; Mea : ≈ 18.3 ppm 
(2E, 4Z): Meb : ≈ 23.8 ppm; Mea : ≈ 19.6 ppm 
 
This pattern allows the two isomers 5a and 6a of 3,5-dimethyl-2,4-hexadienoic acid formed by the 
pyrone ring opening/cross coupling under different experimental conditions to be unambiguously 
assigned (Figure S-2); in addition, the configuration of the 2Z-isomer was corroborated by X-ray 
diffraction (see above). Based on this evidence, all other products were assigned analogously; a 




Figure S-2. Comparison of the 1H NMR spectra (CDCl3) of 6a (top) and 5a (bottom) shows the 
characteristic shift differences of the two geometric isomers 
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Figure S-3. The configuration of compound 5e was assigned based on the characteristic shift pattern 




General. All reactions were carried out in flame-dried glassware under Argon. All solvents were 
purified by distillation over the drying agents indicated and were transferred under Argon: THF (Mg-
anthracene), diethyl ether (Mg-anthracene), dichloromethane (CaH2), acetonitrile (CaH2), 
triethylamine (CaH2), hexane (Na/K), toluene (Na/K). HOAc and MeOH were used as received. Flash 
chromatography: Merck silica gel 60 (230-400 mesh). IR: Nicolet FT-7199 spectrometer, 
wavenumbers in cm−1. MS (EI): Finnigan MAT 8200, MS (CI): Finnigan MAT 95, MS (ESI) ESQ 3000; 
accurate mass determinations: Bruker APEX III FT-MS (7 T magnet). NMR: Spectra were recorded on 
a Bruker DPX 300, AV 400 or AV 500 spectrometer in the solvents indicated; chemical shifts (δ) are 
given in ppm relative to TMS, coupling constants (J) in Hz. The solvent signals were used as 
references (CDCl3: δH = 7.24 ppm, δC = 77.0 ppm) and the chemical shifts converted to the TMS scale. 
Unless stated otherwise, all commercially available compounds (Acros, Sigma-Aldrich, Fluka, Alfa 







2-Pyrone, 4,6-dimethyl-2-pyrone, 6-pentyl-2-pyrone, coumarin, and 4H-chromen-4-one were 
purchased and used as received; compounds 4i,2 4k,3 4j,4 4l,5 and 136 were prepared according to the 
literature. 
 
Compound 1. The solution of triflic anhydride (4.23 g, 15 mmol) in CH2Cl2 (5 mL) was slowly added at 
20oC to a stirred solution of 4-hydroxy-6-methyl-2-pyrone (1.43 g, 11 mmol) and 
triethylamine (1.52 g, 15 mmol) in CH2Cl2 (15 mL). Once the addition was complete, the 
cooling bath was removed and stirring continued overnight at ambient temperature. For 
work up, the mixture was washed with HCl aq (1 M) and the aqueous layer extracted with CH2Cl2 (3 x 
10 mL). The combined organic phases were dried over MgSO4 and evaporated, and the residue was 
purified by flash chromatography (hexane/EtOAc, 8:1) to give the title compound as a pale yellow oil 
(2.35 g, 83%). The spectral and analytical data were identical to those reported in the literature.7 1H 
NMR (400 MHz, CDCl3): δ = 2.33 (s, 3H), 6.05 (s, 1H), 6.11 (s, 1H). 
13C NMR (100 MHz, CDCl3): δ = 20.3, 
99.6, 102.4, 118.4 (q, JC,F = 318.8 Hz) (113.6, 116.8, 120.0, 123.2), 160.9, 161.5, 165.5. MS (EI): m/z 
(%) 258 (100), 229 (51), 165 (7), 123 (20), 113 (27), 97 (100), 69 (98). 
Representative Procedure for the Preparation of 6-Alkyl-2-pyrone Derivatives. 6-Ethyl-4-methyl-
2H-pyran-2-one (4e).8,9 A mixture of ethyl 3-methyl-2-butenoate (0.64 g, 5 mmol) and 
propanoyl chloride (0.55 g, 6 mmol) in CH2Cl2 (5 mL) was added to a stirred and cooled 
suspension of AlCl3 (1.60 g, 12 mmol) and CH2Cl2 (15 mL) at a rate as to maintain gentle 
reflux. Once the addition was complete, the mixture was stirred under reflux for 3 h 
before it was cooled and carefully decomposed by slowly pouring it into excess ice-water. The 
aqueous layer was separated and extracted with CH2Cl2 (3 x 10 mL), and the combined organic layer 
were dried over MgSO4 and evaporated. The residue was added to a mixture of conc. H2SO4 (10 mL) 
and HOAc (20 mL) and the resulting solution stirred at 40 oC until TLC control indicated complete 
conversion. The mixture was carefully poured into crushed ice and the resulting phase was 
neutralized with sat. aq. Na2CO3. Extraction of the aqueous layer with EtOAc (3 x 30 mL), drying of 
the combined organic phases over Na2SO4 and evaporation of the solvent gave a residue that was 
purified by flash chromatography (hexane/EtOAc, 4:1) to give the title compound as a yellow liquid 
(529 mg, 77%). 1H NMR (400 MHz, CDCl3): δ = 1.21 (t, J = 7.6 Hz, 3H), 2.12 (s, 3H), 2.49 (q, J = 7.4 Hz, 
2H), 5.83 (s, 1H), 5.94 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 11.0, 21.4, 26.8, 104.8, 110.6, 156.2, 
163.3, 166.0. IR (film, cm-1): 2981, 1769, 1731, 1712, 1698, 1643, 1561, 1437, 1408, 1377, 1225, 1133, 
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1063, 1030, 995, 913, 891, 861, 830. MS (EI): m/z (%) 138 (52), 110 (62), 109 (100), 95 (85), 67 (8), 53 
(81), 39 (9). 
 
The following compounds were prepared analogously:  
Compound 4d.8,9 1H NMR (400 MHz, CDCl3): δ = 1.21 (d, J = 6.9 Hz, 6H), 2.11(s, 3H), 2.65-2.72 (m, 1H), 
5.81 (s, 1H), 5.91 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 20.1, 21.5, 32.5, 103.4, 110.6, 
156.2, 163.2, 169.5. IR (film, cm-1): 3082, 2973, 2936, 2877, 1769, 1724, 1698, 1642, 
1561, 1442, 1409, 1378, 1366, 1311, 1226, 1123, 1081, 1068, 1026, 974, 942, 881, 835. 
MS (EI): m/z (%) 152 (22), 124 (18), 109 (100), 53 (28), 27 (5). 
Compound 4f. Yellow liquid. 1H NMR (400 MHz, CDCl3): δ = 0.91-0.95 (m, 2H), 1.04-1.08 (m, 2H), 
1.68-1.75 (m, 1H), 2.09 (s, 3H), 5.86 (s, 1H), 5.90 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 
8.0, 14.0, 21.3, 104.4, 109.4, 156.5, 163.0, 165.5. IR (film, cm-1): 3082, 3014, 1713, 
1638, 1549, 1442, 1415, 1378, 1227, 1189, 1161, 1062, 1028, 952, 864, 850, 811. MS 
(EI): m/z (%) 150 (65), 122 (100), 109 (40), 93 (25), 79 (61), 69 (10), 53 (55), 39 (21), 27 
(14). HRMS (EI): m/z: calcd for C9H10O2 [M]: 150.06794, found: 150.06808. 
Compound 4g.8,9 Pale yellow syrup. 1H NMR (400 MHz, CDCl3): δ = 2.14 (s, 3H), 2.89 (t, J = 6.5 Hz, 2H), 
3.79 (t, J = 6.5 Hz, 2H), 5.95 (s, 1H), 6.01 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 21.4, 
36.7, 40.4, 107.8, 111.7, 155.8, 159.6, 162.6. IR (film, cm-1): 2967, 1843, 1768, 1724, 
1698, 1647, 1562, 1441, 1406, 1379, 1294, 1226, 1132, 1032, 980, 929, 891, 853, 
831. MS (EI): m/z (%) 174 (8), 172 (24), 146 (10), 144 (31), 109 (53), 95 (100), 79 (6), 
53 (51), 27 (14). HRMS (EI): m/z: calcd for C8H9O2Cl [M]: 172.02895, found: 172.02911. 
Compound 4h.10 A mixture containing compound 4g (172.5 mg, 1 mmol) and NaI (300 mg, 2 mmol) in 
anhydrous acetone was refluxed for 20 h. Evaporation of the solvent followed by 
flash chromatography (hexane/EtOAc, 4:1) furnished the title compound as a pale 
yellow solid. 1H NMR (400 MHz, CDCl3): δ = 2.16 (s, 3H), 3.01 (t, J = 7.0 Hz, 2H), 3.39 
(t, J = 7.0 Hz, 2H), 5.91 (s, 1H), 6.02 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 0.6, 21.5, 
37.5, 107.2, 111.7, 155.8, 161.2, 162.6. IR (film, cm-1): 3416, 3074, 3040, 2982, 2957, 2915, 2854, 
2287, 1717, 1641, 1616, 1561, 1471, 1438, 1425, 1399, 1373, 1328, 1293, 1243, 1226, 1171, 1154, 
1144, 1118, 1024, 969, 948, 916, 876, 853, 844, 737. MS (EI): m/z (%) 264 (29), 236 (8), 136 (7), 109 
(100), 95 (9), 79 (13), 53 (41). HRMS (EI): m/z: calcd for C8H9O2I [M]: 263.96450, found: 263.96473. 
Compound 4r.8,9 Pale yellow solid. 1H NMR (400 MHz, CDCl3): δ = 1.64-1.72 (m, 4H), 2.11 (s, 3H), 2.34 
(t, J = 6.9 Hz, 2H), 2.47 (t, J = 7.3 Hz, 2H), 3.67 (s, 3H), 5.84 (s, 1H), 5.95 (s, 
1H). 13C NMR (100 MHz, CDCl3): δ = 21.4, 24.2, 26.2, 33.3, 33.6, 51.6, 105.9, 
110.8, 156.1, 163.2, 164.1, 173.7. IR (film, cm-1): 2953, 2869, 1729, 1644, 
1561, 1437, 1408, 1377, 1199, 1174, 1078, 1029, 857. MS (EI): m/z (%) 224 
(13), 192 (21), 164 (7), 149 (9), 137 (100), 109 (40), 95 (13), 53 (30). HRMS (ESI+): m/z: calcd for 
C12H16O4Na [M+Na
+]: 247.09362, found: 247.09408. 
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Compound 7.11 Colorless oil. 1H NMR (400 MHz, CDCl3): δ = 0.10 (s, 3H), 0.00 (s, 3H), 0.81 (s, 9H), 
1.20 (d, J = 5.9 Hz, 3H), 2.51-2.59 (m, 2H), 4.18-4.26 (m, 1H), 6.01 (d, J = 6.6 Hz, 
1H), 6.16 (d, J = 9.2 Hz, 1H), 7.24 (dd, J = 6.4 Hz, J =  9.4 Hz, 1H). 13C NMR (100 
MHz, CDCl3): δ = 5.2, 4.7, 17.9, 24.0, 25.7, 44.2, 66.2, 104.8, 113.4, 143.5, 
162.8, 163.9. IR (film, cm-1): 2956, 2930, 2893, 2857, 1732, 1636, 1559, 1472, 1463, 1378, 1362, 1255, 
1217, 1128, 1091, 995, 939, 893, 836, 807, 776, 721, 661. MS (EI): m/z (%) 268 (0.1), 211 (100), 167 
(32), 159 (5), 139 (32), 111 (17), 95 (4), 73 (21), 59 (4), 39 (6). HRMS (ESI+): m/z: calcd for 
C14H24O3SiNa [M+Na
+]: 291.13841, found: 291.13869. 
Compound 10.8,9 Pale yellow liquid. 1H NMR (400 MHz, CDCl3): δ = 0.86 (t, J = 6.9 Hz, 3H), 1.26-1.32 
(m, 8H), 1.59-1.67 (m, 2H), 2.10 (s, 3H), 2.43 (t, J = 7.6 Hz, 2H), 5.82 (s, 1H), 
5.92 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.0, 21.4, 22.5, 26.8, 28.8, 28.9, 
31.6, 33.6, 105.6, 110.5, 156.1, 163.3, 165.0. IR (film, cm-1): 2954, 2927, 
2856, 1724, 1644, 1561, 1465, 1441, 1406, 1377, 1224, 1148, 1132, 1105, 1024, 961, 833, 816, 724, 
681. MS (EI): m/z (%) 208 (32), 180 (12), 163 (8), 151 (6), 137 (36), 124 (37), 109 (100), 95 (64), 82 
(35), 67 (14), 53 (73), 41 (26). HRMS (EI): m/z: calcd for C13H20O2 [M]: 208.14615, found: 208.14633. 
Compound 4m.5 4-Fluorobenzyl bromide (1.13 g, 6 mmol) and K2CO3 (1.03 g, 7.5 mmol) were added 
to a solution of 4-hydroxy-6-methyl-2-pyrone (0.63 g, 5 mmol) in anhydrous DMF 
and the resulting mixture was stirred for 3 h under Ar. For work up, the mixture 
was diluted with aq. sat. NH4Cl (30 mL), the aqueous phase was extracted with 
EtOAc (3 x 20 mL), the combined organic phases were dried over MgSO4 and 
evaporated, and the resiude purified by flash chromatography (hexane/EtOAc, 3:1) to give the title 
compound as a white solid (585 mg, 50%). 1H NMR (400 MHz, CDCl3): δ = 2.21 (s, 3H), 4.97 (s, 2H), 
5.48 (s, 1H), 5.82 (s, 1H), 7.07-7.11 (m, 2H), 7.33-7.37 (m, 2H). 13C NMR (100 MHz, CDCl3): δ = 19.8, 
69.9, 88.5, 100.4, 115.7+115.9 (d, JF-C = 22.1 Hz), 129.7+129.8 (d, JF-C = 8.0 Hz), 130.22+130.25 (d, JF-C = 
3.0 Hz), 161.7+164.1 (d, JF-C = 246.2 Hz), 162.3, 164.8, 170.1. IR (film, cm
-1): 1742, 1727, 1651, 1605, 
1571, 1515, 1458, 1379, 1322, 1259, 1226, 1188, 1161, 1148, 1040, 1015, 953, 867, 825, 816. MS (EI): 
m/z (%) 234 (4), 150 (3), 109 (100), 83 (9), 43 (4). HRMS (ESI+): m/z: calcd for C13H11FO3Na [M+Na
+]: 
257.05846, found: 257.05844. 
Compound 4q. A solution of TBSCl (83 mg, 0.55 mmol) in CH2Cl2 (2 mL) was added dropwise to a 
solution of 6-hydroxymethyl-4-methyl-2H-pyran-2-one (70 mg, 0.5 mmol)12 and 
imidazole (37.4 mg, 0.55 mmol) in CH2Cl2 (5 mL) and the resulting mixture was 
stirred for 2 h. A standard extractive work up followed by flash chromatography 
(hexanes/EtOAc, 4:1) gave the title compound as a colorless solid. 1H NMR (400 
MHz, CDCl3): δ = 0.12 (s, 6H), 0.94 (s, 9H), 2.16 (s, 3H), 4.42 (s, 2H), 5.97 (s, 1H), 6.12 (s, 1H). 
13C NMR 
(100 MHz, CDCl3): δ = 5.5, 18.3, 21.7, 25.8, 61.3, 103.9, 111.5, 156.2, 162.3, 163.3. IR (film, cm
-1): 
2954, 2929, 2857, 2886, 1732, 1651, 1568, 1472, 1409, 1387, 1368, 1299, 1254, 1227, 1151, 1119, 
1007, 954, 830, 779. MS (EI): m/z (%) 239 (2), 197(100), 169 (51), 153 (4), 141 (5), 125 (11), 109 (4), 
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95 (59), 75 (42), 53 (9), 41 (8). HRMS (ESI+): m/z: calcd for C13H22O3SiNa [M+Na
+]: 277.12314, found: 
277.12304. 
 
Iron Catalyzed Cross Coupling of 4-Triflyloxy-2-pyrones 
 
Representative Procedure: Preparation of 4-Isopropyl-6-methyl-2H-pyran-2-one (2c). A solution of 
isopropylmagnesium bromide (2 M in THF, 1.25 mmol, 0.63 mL) was quickly added via 
syringe at 78 oC to a vigorously stirred solution of Fe(acac)3 (8.8 mg, 0.025 mmol,) and  
4-trifloxy-6-methyl-2-pyrone (129.0 mg, 0.5 mmol) in THF (5.0 mL) and NMP (0.5 mL). 
Stirring was continued at this temperature for 20 min before the reaction was quenched 
with sat. aq. NH4Cl. The pH value of the aqueous phase was adjusted to 2~3 by addition of HCl (1 M) 
before it was extracted with EtOAc (5 x 20 mL). The combined organic layers were dried over Na2SO4 
and evaporated, and the residue was purified by flash chromatography (hexane/EtOAc, 6:1) to give 
the title compound as a colorless oil (59.7 mg, 78%). 1H NMR (400 MHz, CDCl3): δ = 1.14 (d, J = 7.0 Hz, 
6H), 2.20 (s, 3H), 2.53-2.63 (m, 1H), 5.87 (s, 1H), 5.92 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 19.8, 
21.2, 33.5, 104.1, 107.5, 161.4, 163.7, 165.8. IR (film, cm-1): 2967, 2932, 2876, 1721, 1644, 1560, 
1467, 1449, 1385, 1366, 1341, 1291, 1224, 1181, 1147, 1126, 1105, 1072, 1026, 979, 941, 871, 850, 
829, 687. MS (EI): m/z (%) 152 (34), 124 (35), 109 (100), 81 (15), 65 (5), 53 (7), 43 (42), 39 (11). HRMS 
(EI): m/z: calcd for C9H12O2 [M]: 152.08379, found: 152.08373. 
The following compounds were prepared analogously: 
Compound 2b. The reaction was performed in Et2O; pale yellow solid (74%). 
1H NMR (400 MHz, 
CDCl3): δ = 0.88 (t, J = 6.6 Hz, 3H), 1.25-1.32 (m, 20H), 1.50-1.60 (m, 4H), 2.22 (s, 3H), 
2.32 (t, J = 7.6 Hz, 2H), 5.84 (s, 1H), 5.93 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.1, 
19.8, 22.7, 25.7, 28.1, 29.1, 29.3, 29.3, 29.5, 29.6, 29.6, 29.7, 31.9, 32.8, 35.2, 105.6, 
109.6, 160.5, 161.3, 163.5. IR (film, cm-1): 2922, 2853, 1732, 1645, 1562, 1465, 1377, 1228, 1028, 848, 
721. MS (EI): m/z (%) 306 (8), 263 (6), 249 (6), 235 (4), 193 (9), 179 (4), 165 (3), 151 (8), 137 (99), 124 
(100), 109 (18), 96 (70), 81 (12), 67 (10), 55 (12), 43 (43). HRMS (ESI+): m/z: calcd for C20H34O2Na 
[M+Na+]: 329.24505, found: 329.24510. 
Compound 2d. Colorless oil (74%). 1H NMR (400 MHz, CDCl3): δ = 0.88 (d, J = 6.6 Hz, 6H), 1.78-1.88 
(m, 1H), 2.18 (s, 3H), 2.18 (d, J = 6.9 Hz, 2H), 5.81 (s, 1H), 5.85 (s, 1H). 13C NMR (100 MHz, 
CDCl3): δ = 19.7, 22.2, 27.8, 44.5, 105.7, 110.4, 159.4, 161.2, 163.2. IR (film, cm
-1): 3382, 
2961, 2874, 1732, 1646, 1467, 1370, 1217, 1167, 942, 819. MS (EI): m/z (%) 166 (38), 151 
(14), 138 (7), 124 (31), 109 (8), 96 (100), 81 (7), 67 (14), 53 (9), 43 (75), 27 (9). HRMS (EI): 
m/z: calcd for C10H14O2 [M]: 166.09921, found: 166.09938. 
Compound 2e. Pale yellow oil (60%). 1H NMR (400 MHz, CDCl3): δ = 1.77-1.84 (m, 2H), 2.12 (s, 3H), 
2.29 (t, J = 7.6 Hz, 2H), 2.57 (t, J = 7.5 Hz, 2H), 5.76 (s, 1H), 5.86 (s, 1H), 7.07-7.13 (m, 
3H), 7.18-7.22 (m, 2H). 13C NMR (100 MHz, CDCl3): δ = 19.7, 29.5, 34.4, 35.0, 105.4, 
109.6, 126.0, 128.3, 128.4, 141.0, 160.0, 161.4, 163.3. MS (EI): m/z (%) 228 (28), 124 
(100), 104 (9), 96 (70), 91 (20), 77 (7), 65 (8), 43 (24). HRMS (ESI+): m/z: calcd for 
C15H16O2Na [M+Na





Iron Catalyzed Ring Opening/Cross Coupling 
 
Representative Procedure for the Iron-Catalyzed Ring-Opening/Cross Coupling of 2-Pyrones to 
afford (2E,4E)-Configured Diene Carboxylic Acids. Preparation of (2E,4E)-5-
Methyldeca-2,4-dienoic Acid (6c). A solution of MeMgBr (3 M in Et2O, 0.75 
mmol, 0.25 mL) was quickly added via syringe to a rapidly stirred solution of 
Fe(acac)3 (4.4 mg, 5 mol%, 0.0125 mmol) and 6-pentyl-2-pyrone 4c (41.5 mg, 0.25 mmol) in 
diethylether (5.0 mL) and toluene (5.0 mL) at 30 oC. The mixture was allowed to reach ambient 
temperature while stirring for 40 min. The reaction was quenched with aq. sat. NH4Cl and the pH of 
the aqueous layer adjusted to 2~3 upon addition of HCl (1 M). The aqueous layer was extracted with 
EtOAc (5 x 20 mL), the combined organic phases were dried over Na2SO4 and evaporated, and the 
residue was purified by flash chromatography (hexane/EtOAc, 6:1) to give the title compound in the 
form of colorless crystals (41.9 mg, 92%) (2E,4E) : (2Z,4E) > 10 : 1). 1H NMR (400 MHz, CDCl3): δ = 0.89 
(t, J = 6.9 Hz, 3H), 1.24-1.35 (m, 4H), 1.43-1.50 (m, 2H), 1.90 (s, 3H), 2.14 (t, J = 7.5 Hz, 2H), 5.78 (d, J = 
15.1 Hz, 1H), 6.03 (d, J = 11.6 Hz, 1H), 7.68 (dd, J = 11.8, 15.1 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 
14.0, 17.4, 22.5, 27.3, 31.5, 40.3, 117.7, 123.0, 143.4, 152.1, 172.9. IR (film, cm-1): ~3600-2300 (br), 
2935, 2857, 1683, 1623, 1608, 1416, 1309, 1282, 1237, 1171, 977, 939, 884, 693. MS (EI): m/z (%) 
182 (9), 167 (7), 137 (14), 125 (6), 122 (6), 111 (100), 97 (36), 93 (21), 81 (37), 79 (25), 77 (14), 67 
(18), 55 (34), 41 (30), 29 (14). HRMS (EI): m/z: calcd for C11H18O2 [M]: 182.13054, found: 182.13068. 
The following compounds were prepared analogously: 
Compound 6b. White solid (88%, (2E,4Z) : (2Z,4Z) = 8 : 1); the NMR spectra are in full accord with 
those reported in the literature;13 IR (film, cm-1): ~3600-2300 (br), 1686, 1628, 1606, 
1417, 1373, 1277, 1201, 1138, 994, 948, 871, 687. MS (EI): m/z (%) 112 (59), 97 
(100), 67 (58), 65 (21), 55 (17), 43 (18), 41 (57), 39 (58). HRMS (EI): m/z: calcd for C6H8O2 [M]: 
112.05233, found: 112.05243. 
Compound 6d. The reaction was performed in THF at 0°C  RT; colorless oil (82%, (2Z,4E):(2E,4E) = 
1:8). 1H NMR (400 MHz, CDCl3): δ = 1.04 (d, J = 6.9 Hz, 6H), 1.80 (s, 3H), 2.24 (s, 
3H), 2.27-2.37 (m, 1H), 5.69 (s, 1H), 5.76 (s, 1H), ~10.0-13.5 (br, 1H). 13C NMR 
(100 MHz, CDCl3): δ = 15.8, 20.1, 21.2, 37.9, 116.9, 125.9, 148.6, 157.6, 172.6. IR 
(film, cm-1): ~3600-2400 (br), 2981, 2935, 1690, 1638, 1561, 1439, 1378, 1292, 1255, 1202, 1157, 
1032, 991, 946, 886, 849, 730, 683. MS (EI): m/z (%) 168 (0.48), 125 (100), 111 (7), 107 (14), 97 (8), 91 
(11), 79 (11), 67 (8), 55 (6), 41 (9). HRMS (EI): m/z: calcd for C10H16O2 [M]: 168.11491, found: 
168.11503. 
Compound 6e. The reaction with hexylmagnesium bromide was performed at 30°C for 60 min; the 
product was isolated as a colorless oil in 84% ((2E,4Z):other isomers > 10 : 
1). 1H NMR (400 MHz, CDCl3): δ = 0.89 (t, J = 6.8 Hz, 3H), 1.24-1.33 (m, 6H), 
1.39-1.45 (m, 2H), 1.80 (s, 3H), 2.18-2.21 (m, 2H), 2.23 (s, 3H), 5.68 (s, 1H), 
5.74 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.0, 19.8, 22.6, 24.4, 28.2, 29.3, 31.6, 33.1, 115.9, 128.5, 
143.4, 157.2, 171.1. IR (film, cm-1): 2927, 2857, 1686, 1620, 1597, 1467, 1418, 1376, 1291, 1251, 
1178, 1146, 933, 890, 725. MS (EI): m/z (%) 210 (1), 195 (4), 125 (100), 109 (8), 97 (15), 81 (10), 67 
(10), 55 (8), 43 (12). HRMS (ESI+): m/z: calcd for C13H22O2Na [M+Na
+]: 233.15115, found: 233.15120. 
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Compound 6f. The reaction with Ph(CH2)3MgBr was performed at 30°C for 60 min; the product was 
isolated as a colorless oil in 82% ((2E,4Z):other isomers > 10 : 1). 1H NMR (400 
MHz, CDCl3): δ = 1.73-1.80 (m, 2H), 1.81 (s, 3H), 2.21 (s, 3H), 2.27 (t, J = 7.8 Hz, 
2H), 2.62 (t, J = 7.8 Hz, 2H), 5.67 (s, 1H), 5.77 (s, 1H), 7.16-7.20 (m, 3H), 7.26-
7.30 (m, 2H). 13C NMR (100 MHz, CDCl3): δ = 19.7, 24.3, 30.1, 32.8, 35.8, 116.4, 125.8, 128.3, 128.4, 
128.9, 142.0, 142.6, 157.0, 171.9. IR (film, cm-1): 3027, 2933, 1682, 1618, 1496, 1453, 1375, 1291, 
1253, 1181, 891, 749, 699. MS (EI): m/z (%) 244 (0.3), 229 (52), 140 (29), 125 (9), 104 (100), 96 (49), 
91 (44), 81 (26), 77 (12), 65 (11), 53 (7), 43 (52). HRMS (CI): m/z: calcd for C16H21O2 [M+H
+]: 
245.15395, found: 245.15415. 
Representative Procedure for the Iron-Catalyzed Ring-Opening/Cross Coupling of 2-Pyrones to 
afford (2Z,4E)-Configured Diene Carboxylic Acids. Preparation of (Z)-3,5-
Dimethyldodeca-2,4-dienoic Acid (11). A solution of MeMgBr (3 M in 
Et2O, 2.5 mL, 7.5 mmol) was quickly added via syringe to a rapidly stirred 
solution of Fe(acac)3 (44.5 mg, 0.125 mmol) and pyrone 10 (520 mg, 2.5 mmol) in diethylether (25 
mL) and toluene (25 mL) at 30 oC. Stirring was continued for 20 min at this temperature before the 
reaction was quenched with aq. sat. NH4Cl and the pH of the aqueous layer adjusted to 2~3 upon 
addition of HCl (1 M). The aqueous layer was extracted with EtOAc (5 x 20 mL), the combined organic 
phases were dried over Na2SO4 and evaporated, and the residue was purified by flash 
chromatography (hexane/EtOAc, 6:1) to give the title compound in the form of a pale yellow liquid 
(460.5 mg, 83%), (2Z,4E) : others > 20 : 1, 1H NMR). 1H NMR (400 MHz, CDCl3): δ = 0.88 (t, J = 6.4 Hz, 
3H), 1.26-1.33 (m, 8H), 1.42-1.49 (m, 2H), 1.73 (s, 3H), 2.04 (s, 3H), 2.10 (t, J = 7.5 Hz, 2H), 5.68 (s, 
1H), 6.40 (s, 1H), ~9.5-13.5 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.1, 18.6, 22.7, 25.7, 27.8, 29.2, 
31.8, 40.9, 116.7, 123.4, 143.5, 156.2, 171.0. IR (film, cm-1): ~3600-2400 (br), 2926, 2855, 1685, 1625, 
1592, 1440, 1377, 1289, 1251, 1201, 1161, 1028, 934, 853, 722, 707. MS (EI): m/z (%) 224 (4), 209 (9), 
179 (6), 125 (100), 111 (6), 107 (14), 95 (11), 93 (12), 79 (12), 67 (7), 55 (9), 41 (16). HRMS (EI): m/z: 
calcd for C14H24O2 [M]: 224.17744, found: 224.17763. 
The following compounds were prepared analogously: 
Compound 5a. Colorless crystals (96%, (2Z:2E > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.76 (s, 3H), 1.86 
(s, 3H), 2.05 (s, 3H), 5.69 (s, 1H), 6.44 (s, 1H), ~10.5-13.0 (br, 1H). 13C NMR (100 
MHz, CDCl3): δ = 20.4, 25.6, 27.3, 116.6, 123.7, 140.0, 156.0, 171.0. IR (film, cm
-1): 
~3600-2400 (br), 2981, 2935, 1690, 1638, 1561, 1439, 1378, 1292, 1255, 1202, 
1157, 1032, 991, 946, 886, 849, 730, 683. MS (EI): m/z (%) 140 (4), 125 (100), 112 (4), 97 (53), 96 (9), 
82 (8), 81 (23), 79 (22), 69 (8), 67 (6), 55 (7), 53 (8), 43 (37), 41 (15), 39 (11). HRMS (EI): m/z: calcd for 
C8H12O2 [M]: 140.08372, found: 140.08373. 
Compound 5b. The reaction was performed at 60°C for 40 min; white solid (86%, (2Z,4E) : (2Z,4Z) = 
1 : 7);  the NMR spectra are in full accord with those reported in the literature;13 IR 
(film, cm-1): ~3600-2300 (br), 1679, 1635, 1600, 1433, 1247, 1224, 1000, 961, 839, 780. 
MS (EI): m/z (%) 112 (59), 97 (100), 67 (58), 65 (21), 55 (17), 43 (18), 41 (57), 39 (58). 
HRMS (EI): m/z: calcd for C6H8O2 [M]: 112.05233, found: 112.05243. 
Compound 5c. The reaction was performed at 60°C for 40 min; white solid, 
(94%, (2E,4E) : (2Z,4E) < 1 : 10). 1H NMR (400 MHz, CDCl3): δ = 0.89 (t, J = 6.6 Hz, 
3H), 1.25-1.35 (m, 4H), 1.44-1.52 (m, 2H), 1.86 (s, 3H), 2.18 (t, J = 6.3 Hz, 2H), 5.58 
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(d, J = 11.5 Hz, 1H), 6.99 (t, J = 11.4 Hz, 1H), 7.17 (d, J = 11.8, 1H), ~10.0-13.5 (br, 1H). 13C NMR (100 
MHz, CDCl3): δ = 14.0, 16.7, 22.5, 27.5, 31.6, 40.7, 113.9, 121.5, 142.9, 152.4, 172.1. IR (film, cm
-1): 
~3600-2300 (br), 2929, 2858, 1682, 1623, 1591, 1440, 1289, 1228, 930, 892, 825, 726. MS (EI): m/z 
(%) 182 (9), 167 (7), 137 (14), 125 (6), 122 (6), 111 (100), 97 (36), 93 (21), 81 (37), 79 (25), 77 (14), 67 
(18), 55 (34), 41 (30), 29 (14). HRMS (EI): m/z: calcd for C11H18O2 [M]: 182.13054, found: 182.13068. 
Compound 5d. Colorless crystals (92%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.04 (d, 
J = 6.9 Hz, 6H), 1.68 (s, 3H), 2.02 (s, 3H), 2.29-2.39 (m, 1H), 5.69 (s, 1H), 6.34 (s, 1H), 
~10.5-13.0 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 15.8, 21.1, 25.7, 37.6, 116.9, 
121.6, 147.7, 156.8, 171.6. IR (film, cm-1): ~3600-2400 (br), 2963, 2874, 1683, 1621, 
1439, 1377, 1288, 1252, 1203, 1156, 1084, 1028, 940, 851, 704. MS (EI): m/z (%) 
168 (0.35), 153 (2), 125 (100), 111 (4), 107 (8), 97 (11), 91 (5), 79 (7), 67 (6), 55 (6), 43 (18). HRMS 
(EI): m/z: calcd for C10H16O2 [M]: 168.11520, found: 168.11503. 
Compound 5e. Colorless crystals (93%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.06 (t, J 
= 7.6 Hz, 3H), 1.75 (s, 3H), 2.05 (s, 3H), 2.13 (q, J = 7.6 Hz, 2H), 5.69 (s, 1H), 6.42 (s, 
1H), ~10.5-13.0 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 12.4, 18.5, 25.6, 33.5, 
116.7, 122.3, 144.6, 156.4, 171.5. IR (film, cm-1): ~3600-2500 (br), 2969, 2938, 2879, 
1682, 1624, 1591, 1439, 1377, 1290, 1249, 1199, 1178, 1156, 1031, 998, 937, 887, 849, 705. MS (EI): 
m/z (%) 154 (1.29), 139 (10), 125 (100), 109 (9), 97 (16), 93 (11), 79 (10), 67 (11), 55 (11), 43 (24), 41 
(16), 39 (13). HRMS (EI): m/z: calcd for C9H14O2 [M]: 154.09946, found: 154.09938. 
Compound 5f. Colorless crystals (90%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 0.56-
0.60 (m, 2H), 0.65-0.69 (m, 2H), 1.47-1.54 (m, 1H), 1.63 (s, 3H), 2.05 (s, 3H), 5.65 (s, 
1H), 6.53 (s, 1H), ~10.5-13.0 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 5.6, 16.2, 20.2, 
25.7, 116.5, 121.8, 144.3, 155.9, 171.5. IR (film, cm-1): ~3600-2400 (br), 3085, 2978, 
1683, 1613, 1439, 1381, 1256, 1150, 1022, 950, 929, 848, 814, 704, 681. MS (ESI+): m/z 167 [M+H], 
333 [2*M+H], 355 [2*M+Na]. HRMS (EI): m/z: calcd for C10H14O2 [M]: 166.09923, found: 166.09938. 
Compound 5g. White solid (90%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.74 (s, 3H), 
2.04 (m, 3H), 2.56 (t, J = 7.3 Hz, 2H), 3.63 (t, J = 7.3 Hz, 2H), 5.73 (s, 1H), 6.38 (s, 1H), ~10.5-13.0 (br, 
1H). 13C NMR (100 MHz, CDCl3): δ = 18.2, 25.4, 42.6, 43.1, 117.6, 126.3, 137.3, 
155.5, 171.3. IR (film, cm-1): ~3500-2300 (br), 2911, 2762, 2585, 1679, 1641, 
1595, 1431, 1384, 1277, 1248, 1193, 926, 863, 843, 738, 714. MS (EI): m/z (%) 
188 (0.06), 173 (7), 125 (100), 109 (9), 97 (30), 91 (7), 79 (10), 67 (10), 53 (9), 43 (33). HRMS (EI): m/z: 
calcd for C9H13O2Cl [M]: 188.06058, found: 188.06041. 
Compound 5h. White solid (68%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.73 (s, 3H), 
2.05 (m, 3H), 2.68 (t, J = 7.6 Hz, 2H), 3.27 (t, J = 7.6 Hz, 2H), 5.74 (s, 1H), 6.37 (s, 
1H), ~10.5-13.0 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 3.35, 17.9, 25.4, 44.3, 
117.5, 125.9, 139.7, 155.6, 171.0. IR (film, cm-1): ~3700-2400 (br), 2964, 1682, 
1621, 1435, 1378, 1290, 1250, 1170, 1026, 943, 887, 725. MS (ESI+): m/z 281 [M+H]. HRMS (ESI+): 
m/z: calcd for C9H13IO2Na [M+Na
+]: 302.98559, found: 302.98524. 
Compound 5i. White solid (72%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.91 (s, 3H), 
1.93 (s, 3H), 3.71 (s, 3H), 5.01 (s, 1H), 6.74 (s, 1H), ~9.5-13.0 (br, 1H). 13C NMR (100 
MHz, CDCl3): δ = 21.0, 27.9, 55.3, 90.2, 118.1, 146.2, 171.1, 172.1. IR (film, cm
-1): 
~3400-2400 (br), 2923, 2852, 1731, 1681, 1639, 1566, 1440, 1377, 1298, 1202, 
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1169, 1129, 1078, 1040, 928, 794, 721. MS (EI): m/z (%) 156 (2), 141 (19), 112 (82), 97 (100), 79 (81), 
67 (90), 53 (18), 44 (12). HRMS (CI): m/z: calcd for C8H13O3 [M+H
+]: 157.08635, found: 157.08647. 
Compound 5j. White solid (80%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.92 (s, 3H), 
1.96 (s, 3H), 3.48 (s, 3H), 5.09 (s, 2H), 5.20 (s, 1H), 6.74 (s, 1H), ~10.5-13.0 (br, 1H). 
13C NMR (100 MHz, CDCl3): δ = 21.0, 28.0, 56.9, 93.5, 94.1, 117.9, 146.4, 168.2, 
172.6. IR (film, cm-1): ~3500-2300 (br), 2938, 1676, 1633, 1568, 1416, 1374, 1288, 
1217, 1199, 1147, 1017, 982, 922, 829, 720. MS (EI): m/z (%) 186 (2), 171 (3), 154 (3), 141 (4), 124 (5), 
109 (3), 95 (6), 83 (21), 55 (13), 45 (100). HRMS (EI): m/z: calcd for C9H14O4 [M]: 186.08903, found: 
186.08921. 
Compound 5k. White solid (88%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.91 (s, 6H), 
4.93 (s, 2H), 5.15 (s, 1H), 6.79 (s, 1H), 7.33-7.39 (m, 5H), ~10.5-13.0 (br, 1H). 13C 
NMR (100 MHz, CDCl3): δ = 21.2, 28.0, 70.5, 91.4, 118.2, 127.8, 128.3, 128.6, 135.4, 
146.4, 170.1, 172.4. IR (film, cm-1): 3032, 2915, 1728, 1650, 1566, 1453, 1375, 1248, 
1138, 1093, 1015, 892, 808, 733, 695. MS (EI): m/z (%) 188 (0.31), 145 (2), 131 (2), 91 (100), 83 (51), 
65 (12), 55 (2), 39 (3). HRMS (ESI+): m/z: calcd for C14H16O3Na [M+Na
+]: 255.09909, found: 255.09917. 
Compound 5l. White solid (85%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.91 (s, 3H), 
1.94 (s, 3H), 3.82 (s, 3H), 4.90 (s, 2H), 5.14 (s, 1H), 6.79 (s, 1H), 6.87-6.89 (m, 1H), 6.93-6.96 (m, 2H), 
7.28-7.31 (m, 1H), ~10.5-13.0 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 21.3, 
28.0, 55.2, 70.4, 91.5, 113.2, 113.8, 118.2, 119.9, 129.7, 136.9, 146.4, 159.8, 
170.0, 172.4. IR (film, cm-1): 3424, 2938, 1703, 1626, 1603, 1587, 1564, 1490, 
1464, 1388, 1361, 1266, 1234, 1179, 1155, 1112, 1040, 1020, 873, 818, 785, 
738, 694. MS (EI): m/z (%) 262 (0.35), 218 (2), 162 (17), 135 (4), 121 (100), 91 (17), 83 (27), 78 (9), 77 
(7), 65 (5), 51 (2), 41 (3), 39 (4). HRMS (EI): m/z: calcd for C15H18O4Na [M+Na
+]: 285.10966, found: 
285.10973. 
Compound 5m. White solid (86%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.89 (s, 3H), 
1.91 (s, 3H), 4.88 (s, 2H), 5.13 (s, 1H), 6.77 (s, 1H), 7.05-7.09 (m, 2H), 7.34-7.37 
(m, 2H), ~9.5-13.0 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 21.2, 28.0, 69.8, 
91.4, 115.5+115.7 (d, JF-C = 21.1 Hz), 118.1, 129.7+129.8 (d, JF-C = 8.5 Hz), 
131.15+131.18 (d, JF-C = 3.0 Hz), 146.5, 161.5+163.9 (d, JF-C = 245.4 Hz), 169.9, 172.2. IR (film, cm
-1): 
3358, 2931, 1888, 1693, 1604, 1562, 1509, 1454, 1417, 1365, 1220, 1156, 1096, 1012, 821, 760, 704, 
666. MS (EI): m/z (%) 250 (2), 150 (2), 109 (100), 83 (13), 69 (2), 57 (2), 39 (4). HRMS (ESI+): m/z: calcd 
for C14H15O3FNa [M+Na
+]: 273.08969, found: 273.08974. 
Compound 5n. Colorless oil (78%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 0.09 (s, 6H), 
0.92 (s, 9H), 1.71 (s, 3H), 2.07 (s, 3H), 4.10 (s, 2H), 5.71 (s, 1H), 6.76 (s, 1H), 
~10.5-13.0 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = -5.4, 15.6, 18.4, 25.5, 25.9, 
68.2, 117.4, 122.0, 141.1, 155.6, 171.3. IR (film, cm-1): ~3500-2500 (br), 2929, 
2856, 1684, 1632, 1594, 1443, 1250, 1200, 1112, 1079, 938, 833, 774, 707, 671. MS (EI): m/z (%) 240 
(10), 213 (7), 195 (4), 171 (28), 169 (20), 127 (7), 125 (16), 115 (5), 97 (6), 89 (21), 75 (100), 73 (44), 
59 (8), 43 (12). HRMS (ESI+): m/z: calcd for C14H26O3SiNa [M+Na
+]: 293.15424, found: 293.15434. 
Compound 5o. Colorless oil (72%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, 
CDCl3): δ = 1.50 (m, 2H), 1.65 (m, 2H), 1.72 (s, 3H), 2.03 (s, 3H), 2.12 (t, J = 7.2 Hz, 
2H), 3.27 (t, J = 7.2 Hz, 2H), 3.67 (s, 3H), 5.69 (s, 1H), 6.37 (s, 1H). 13C NMR (100 
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MHz, CDCl3): δ = 18.4, 24.3, 25.6, 27.1, 33.9, 40.2, 51.5, 116.9, 123.9, 142.2, 155.9, 170.4, 174.2. IR 
(film, cm-1): ~3600-2500 (br), 2938, 1735, 1682, 1624, 1589, 1435, 1375, 1251, 1200, 1144, 1083, 
1021, 927, 852, 706. MS (EI): m/z (%) 209 (0.84), 196 (3), 181 (3), 163 (2), 149 (5), 125 (100), 107 (25), 
97 (19), 81 (10), 67 (12), 55 (9). HRMS (ESI+): m/z: calcd for C13H20O4Na [M+Na
+]: 263.12525, found: 
263.12538. 
Compound 5p. Colorless oil (68%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.05 (d, J = 
6.8 Hz, 6H), 1.60 (s, 3H), 1.84 (s, 3H), 2.39-2.49 (m, 1H), 5.76 (s, 1H), 5.84 (s, 1H). 13C 
NMR (100 MHz, CDCl3): δ = 19.7, 21.2, 25.9, 37.1, 114.6, 121.1, 138.9, 164.9, 171.0. IR 
(film, cm-1): ~3600-2400 (br), 2967, 2933, 2875, 1697, 1625, 1465, 1415, 1384, 1291, 
1238, 1183, 1023, 943, 871, 667. MS (EI): m/z (%) 168 (0.48), 153 (100), 125 (19), 111 (41), 97 (12), 83 
(16), 67 (17), 55 (14), 43 (87). HRMS (EI): m/z: calcd for C10H16O2 [M]: 168.11496, found: 168.11503. 
Compound 5q. Pale yellow oil (84%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 0.88 (d, J = 
6.8 Hz, 6H), 1.66 (s, 3H), 1.72-1.81 (m, 1H), 1.83 (s, 3H), 2.11 (d, J = 7.2 Hz, 2H), 5.69 
(s, 1H), 5.97 (s, 1H), ~9.0-12.0 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 20.0, 22.4, 
26.4, 27.1, 48.9, 117.2, 122.7, 138.7, 159.1, 171.3. IR (film, cm-1): ~3600-2400 (br), 
2957, 2931, 2870, 1689, 1618, 1465, 1415, 1368, 1291, 1246, 1194, 1164, 979, 884, 
822, 712. MS (EI): m/z (%) 182 (2), 167 (100), 139 (9), 125 (25), 111 (23), 96 (12), 81 (19), 67 (8), 55 
(10), 43 (69), 27 (7). HRMS (EI): m/z: calcd for C11H18O2 [M]: 182.13051, found: 182.13068. 
Compound 5r. Pale yellow oil (73%, (2Z,4E):(2E,4E) > 20:1). 1H NMR (400 MHz, CDCl3): δ = 1.56 (s, 
3H), 1.67-1.74 (m, 2H), 1.76 (s, 3H), 2.20 (t, J = 7.5 Hz, 2H), 2.53 (t, J = 7.7 Hz, 2H), 
5.66 (s, 1H), 5.94 (s, 1H), 7.07-7.13 (m, 3H), 7.17-7.22 (m, 2H). 13C NMR (100 MHz, 
CDCl3): δ = 20.0, 26.4, 29.8, 35.4, 38.6, 116.5, 122.5, 125.9, 128.3, 128.4, 138.9, 
141.7, 159.6, 171.1. IR (film, cm-1): ~3600-2500 (br), 3027, 2934, 2860, 1688, 1622, 1496, 1453, 1416, 
1378, 1292, 1245, 1195, 1079, 1030, 873, 748, 699. MS (EI): m/z (%) 244 (0.29), 229 (52), 140 (29), 
125 (9), 104 (100), 96 (49), 91 (44), 81 (26), 77 (12), 65 (11), 53 (7), 43 (52). HRMS (CI): m/z: calcd for 
C16H21O2 [M+H
+]: 245.15395, found: 245.15415. 
Compound 8. The reaction was performed at 60°C for 40 min; colorless oil (80%, (2Z,4E):(2E,4E) > 
10:1). 1H NMR (400 MHz, CDCl3): δ = 0.00 (s, 3H), 0.04 (s, 3H), 0.86 (s, 9H), 
1.15 (d, J = 6.0 Hz, 3H), 1.89 (s, 3H), 2.23-2.37 (m, 2H), 3.97-4.05 (m, 1H), 5.60 
(d, J = 11.4 Hz, 3H), 6.97 (t, J = 11.7 Hz, 1H), 7.18 (d, J = 11.7 Hz, 1H). 13C NMR 
(100 MHz, CDCl3): δ = 4.9, 4.5, 17.8, 18.0, 23.9, 25.8, 50.7, 67.7, 114.3, 124.0, 142.3, 148.8, 171.7. 
IR (film, cm1): 3420, 2931, 2858, 1705, 1378, 1256, 1175, 1132, 993, 835, 777, 669. MS (EI): m/z (%) 
240 (5), 227 (17), 209 (15), 183 (34), 159 (62), 135 (9), 119 (17), 115 (26), 107 (17), 103 (21), 91 (11), 
75 (100), 73 (90), 59 (13), 41 (9). HRMS (ESI+): m/z: calcd for C15H28O3SiNa [M+Na
+]: 307.16998, 
found: 307.16999. 
Granulatamide B. Triethylamine (45.5 mg, 0.45 mmol), 1-hydroxybenzotriazole (44.6 mg, 0.33 mmol) 
and EDC·HCl (86.3 mg, 0.45 mmol) were added to a solution of 
tryptamine (52.8 mg, 0.33 mmol) and acid 11 (67.2 mg, 0.30 
mmol) in DMF (0.3 mL) and CH2Cl2 (5 mL). The mixture was 
stirred overnight before the solvent was evaporated. The residue 
was treated with water (15 mL) and extracted with ethyl acetate 
(3 x 20 mL). The combined organic layers were washed successively with aq. citric acid solution (5%, 3 
S-14 
 
x 20 mL), sat. aq. NaHCO3 (3 x 30 mL) and brine (50 mL). The organic phase was dried over Na2SO4 
and evaporated, and the residue purified by flash chromatography (hexane/EtOAc, 4:1) to give the 
title compound as colorless oil (90.0 mg, 82%). The spectral data are in agreement with those 
reported in the literature.14 1H NMR (400 MHz, CDCl3): δ = 0.89 (t, J = 6.7 Hz, 3H), 1.17-1.32 (m, 10H), 
1.56 (s, 3H), 1.83 (t, J = 7.3 Hz, 2H), 1.86 (s, 3H), 2.96 (t, J = 6.9 Hz, 2H), 3.64 (q, J = 6.6 Hz, 2H), 5.68 (s, 
1H), 5.86 (s, 1H), 6.21 (br, 1H), 6.99 (s, 1H), 7.08-7.12 (m, 1H), 7.17-7.20 (m, 1H), 7.36 (d, J = 8.2 Hz, 
1H), 7.58 (d, J = 7.9 Hz, 1H), 8.48 (br, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.0, 17.7, 22.6, 25.3, 25.4, 
27.8, 29.1, 29.3, 31.8, 39.5, 39.5, 111.2, 112.9, 118.6, 119.2, 121.9, 122.0, 122.3, 122.8, 127.3, 136.4, 
142.3, 145.8, 166.8. IR (film, cm-1): 3403, 3278, 3056, 2925, 2853, 1643, 1598, 1522, 1456, 1435, 
1375, 1339, 1260, 1229, 1097, 1031, 1010, 923, 841, 804, 737. MS (EI): m/z (%) 366 (13), 267 (29), 
224 (13), 143 (100), 130 (25), 124 (6), 95 (5), 77 (5), 55 (5), 43 (5). HRMS (ESI+): m/z: calcd for 
C24H34N2ONa [M+Na
+]: 389.25598, found: 389.25633. 
                                                          
14
  F. Reyes, R. Martín, R. Fernández, J. Nat. Prod. 2006, 69, 668–670. 
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